IKT

Inhibikase Therapeutics Inc

1.52

Nov 13 • 3:59 PM ET -0.01 (-0.65%)

1.52

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: GOSS INSM TENX LQDA MNKD KROS UTHR VCRE PLRX MRK

| Held by: VTI IWM VXF IWN VTWO IWC VTWV SBIO AVSC RSSL

Scroll to Statements

Index	RUT
Market Cap	213.21M
Enterprise Value	19.89M
Income	-69.17M
Sales	0.00M
Book/sh	1.35
Cash/sh	1.38
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	35
IPO	Dec 23, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.13
P/C	1.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.34
Current Ratio	15.34
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.41
EPS next Y	-0.45
EPS next Q	-0.11
EPS this Y	12.93%
EPS next Y	-6.59%
EPS next 5Y	5.82%
EPS past 3/5Y	51.48% 22.00%
Sales past 3/5Y	- -
EPS Y/Y TTM	28.48%
Sales Y/Y TTM	-100.00%
EPS Q/Q	21.58%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	9.99% -

Insider Own	22.35%
Insider Trans	0.00%
Inst Own	75.05%
Inst Trans	12.99%
ROA	-49.17%
ROE	-52.87%
ROIC	-36.64%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.80%
SMA50	-19.81%
SMA200	-21.25%
Trades

Shs Outstand	140.27M
Shs Float	108.92M
Short Float	17.84%
Short Ratio	34.31
Short Interest	19.43M
52W High	2.61 -41.76%
52W Low	1.40 8.57%
Volatility	8.18% 7.60%
ATR (14)	0.12
RSI (14)	42.04
Beta	0.95
Rel Volume	0.58
Avg Volume	566.25K
Volume	330,477

Perf Week	1.33%
Perf Month	-16.94%
Perf Quarter	-36.40%
Perf Half Y	-12.14%
Perf YTD	-25.85%
Perf Year	-5.00%
Perf 3Y	62.15%
Perf 5Y	-87.40%
Perf 10Y	-
Recom	1.20
Target Price	5.55
Prev Close	1.53
Price	1.52
Change %	-0.65%

Consensus

Strong Buy

Avg. Price Target

$5.55

Implied Upside

+265.1%

Analysts6incl. previous ratings

Rating Distribution5 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 13, 2026	Initiated	CChardan Capital Markets	Neutral	$1.50	-1.3%
Jun 10, 2026	Initiated	OOppenheimer	Outperform	$5	+228.9%
Mar 04, 2026	Initiated	LLadenburg Thalmann	Buy	$4	+163.2%
Jan 21, 2026	Initiated	BBofA Securities	Buy	$6	+294.7%
Dec 26, 2025	Initiated	HH.C. Wainwright	Buy	$8	+426.3%
Dec 11, 2025	Initiated	CCantor Fitzgerald	Overweight	$4	+163.2%
Feb 12, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral

Nov-10-26 04:01PM	Inhibikase Therapeutics Announces Third Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire) -7.74% +5.16%
Oct-27-26 08:00AM	Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026 (GlobeNewswire)
Oct-20-26 04:01PM	Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors (GlobeNewswire)
Oct-02-26 04:01PM	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-26 04:01PM	Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire)
08:00AM	Loading…
Jul-23-26 08:00AM	Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH (GlobeNewswire) +7.37%
Jul-14-26 08:00AM	Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility (GlobeNewswire) +5.10%
Jul-02-26 04:01PM	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 04:01PM	Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity (GlobeNewswire) -5.42%
Apr-07-26 08:00AM	Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-03-26 02:01PM	Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-26 04:01PM	Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
Feb-22-26 06:15AM	Bank of America Predicts Up to 240% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-20-25 09:54PM	Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:12PM	Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Loading…
04:01PM	Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension (GlobeNewswire)
Nov-14-25 04:01PM	Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
Aug-19-25 08:00AM	Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer (GlobeNewswire)
Aug-14-25 04:50PM	Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
May-14-25 04:05PM	Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity (GlobeNewswire)
May-02-25 05:07AM	Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH (Seeking Alpha)
Apr-14-25 08:00AM	Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer (GlobeNewswire)
Mar-27-25 04:01PM	Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-05-25 09:55AM	Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-24-25 08:00AM	Inhibikase Announces Expansion of Senior Leadership Team (GlobeNewswire) -16.50%
Feb-18-25 08:00AM	Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth (GlobeNewswire) +10.64%
Nov-14-24 08:37AM	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity (GlobeNewswire)
Oct-23-24 06:31AM	Inhibikase Therapeutics Secures Funding and Strengthens Leadership (TipRanks) +15.17%
Oct-22-24 09:07PM	Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc (GuruFocus.com)
Oct-21-24 09:05AM	Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension (GlobeNewswire)
01:01AM	Loading…
Oct-18-24 01:01AM	Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc (GuruFocus.com) -9.36%
Oct-11-24 05:57PM	Inhibikase Therapeutics Secures $110M for Drug Development (TipRanks) +13.08% +8.16%
01:02PM	Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares (GuruFocus.com)
Oct-10-24 08:59AM	Inhibikase Therapeutics Unveils PAH and Parkinsons Drug Pipeline (TipRanks)
Oct-09-24 09:18AM	Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension (GlobeNewswire) +5.88%
Aug-14-24 04:25PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire) -5.80% -5.38%
Aug-07-24 08:00AM	Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Jun-17-24 08:05AM	Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease (GlobeNewswire) +12.77%
Jun-05-24 08:05AM	Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs (GlobeNewswire)
May-20-24 08:01AM	Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million (GlobeNewswire) +7.51%
May-19-24 08:09AM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-16-24 06:52AM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.56%
May-15-24 08:00PM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire) +29.22%
08:45AM	Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement (GlobeNewswire)
May-09-24 08:00AM	Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-18-24 04:30PM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Apr-03-24 08:05AM	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension (GlobeNewswire)
Apr-02-24 10:25AM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 09:06PM	Q4 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.09%
Mar-27-24 10:53PM	IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:15PM	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity (GlobeNewswire)
Mar-07-24 08:30AM	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (GlobeNewswire)
Feb-28-24 04:05PM	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Feb-15-24 09:55AM	Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now (Zacks) -6.69%
Feb-07-24 07:55AM	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers (GlobeNewswire) -8.72%
Jan-29-24 09:05AM	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib (GlobeNewswire) +8.45%
Jan-22-24 12:00PM	Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-16-24 04:05PM	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli (GlobeNewswire) +10.69% -6.25%
Dec-19-23 08:30AM	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs (GlobeNewswire)
Dec-04-23 08:35AM	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro (GlobeNewswire)
Nov-14-23 04:30PM	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity (GlobeNewswire)
Nov-07-23 09:28AM	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 (GlobeNewswire)
08:00AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment (GlobeNewswire) +5.92%
Oct-04-23 08:30AM	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy (GlobeNewswire) -26.43%
Sep-20-23 08:30AM	Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity (GlobeNewswire) +17.82%
Aug-24-23 08:30AM	Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib (PR Newswire)
Aug-22-23 08:05AM	Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders (PR Newswire) -10.33%
Aug-21-23 08:30AM	Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib (PR Newswire)
Aug-17-23 08:30AM	Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro (PR Newswire)
Aug-15-23 11:47PM	Q2 2023 Inhibikase Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -6.02%
Aug-14-23 04:20PM	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity (PR Newswire)
Aug-07-23 08:05AM	Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023 (PR Newswire)
Jul-17-23 04:05PM	Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Jun-29-23 09:29AM	Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split (PR Newswire)
Jun-22-23 08:05AM	Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study (PR Newswire) +9.64%
Jun-21-23 08:05AM	Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease (PR Newswire)
May-30-23 08:05AM	Inhibikase Therapeutics to Present at the LD Micro Invitational XIII (PR Newswire)
May-24-23 12:04PM	Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology (News Direct)
May-17-23 06:11AM	Inhibikase Therapeutics First Quarter 2023 Earnings: US$0.16 loss per share (vs US$0.18 loss in 1Q 2022) (Simply Wall St.)
May-16-23 07:45AM	Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2 '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease (PR Newswire)
May-15-23 08:30AM	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity (PR Newswire) +7.72%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 08:05AM	Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023 (PR Newswire)
May-04-23 08:05AM	Inhibikase Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference (PR Newswire) +6.62%
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-26-23 08:00AM	Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease (PR Newswire) -7.90%
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -6.42%
Apr-21-23 08:30AM	Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase (PR Newswire)
Apr-07-23 10:25PM	Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 08:22AM	Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity (PR Newswire)
Mar-23-23 05:15PM	Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023 (PR Newswire) +8.66%
Mar-21-23 08:00AM	Inhibikase Therapeutics to Present at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (PR Newswire)
Mar-16-23 08:30AM	Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023 (PR Newswire)
Mar-15-23 08:35AM	Inhibikase Therapeutics Provides Interim Update on the '501' Bioequivalence Study of IkT-001Pro (PR Newswire)
Mar-08-23 08:30AM	Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Multiple System Atrophy (PR Newswire)
Feb-15-23 04:05PM	Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire) +7.81%
Feb-08-23 01:00PM	Inhibikase Therapeutics raises $10M as disease treatments show success (American City Business Journals) +5.25%
Jan-27-23 04:05PM	Inhibikase Therapeutics Announces Closing of $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules (PR Newswire) -7.32% +6.55%
Jan-25-23 01:00PM	Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire) -5.49%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERMAN DENNIS N	Director	Jul 30 '26	Option Exercise	1.26	21,854	27,536	21,854	Jul 31 04:05 PM
Sands Capital Life Sciences Pu	10% Owner	Nov 21 '25	Buy	1.45	2,068,965	2,999,999	13,018,965	Nov 24 03:47 PM

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.

CEO & DirectorMr. Mark T. Iwicki

M.D.Dr. Christopher H. Cabell FACC

BECMr. David John McIntyre B.Econs(Acc)

Chief Scientific OfficerDr. John Adams Ph.D.

Chief Human Resources OfficerMr. Jeffrey J. Kagy

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

IKT

Inhibikase Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.